Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inhibiting pyruvate carboxylase as a potential therapeutic strategy for alleviating rheumatoid arthritis.

Inflammopharmacology·2026
Same author

Poor Compliance With Radiotherapy Was Associated With Worse Survival Outcome in Patients With Head and Neck Cancer.

Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons·2026
Same author

Association of carotid revascularization with epilepsy and seizures in patients with carotid stenosis.

Epilepsia·2026
Same author

The angioarchitecture of the vein of Labbé: a population-based-study of 200 Asian hemispheres.

Neuroradiology·2026
Same author

Association of Postlaminectomy Syndrome with Cardiovascular Events in Patients Undergoing Posterior Lumbar Fusion.

Pain medicine (Malden, Mass.)·2026
Same author

Decreased expression of circ-CCDC134 mediated by TNF-α in patients with rheumatoid arthritis affects T cell function via targeting protein phosphatase 2A.

Arthritis research & therapy·2026

Related Experiment Video

Updated: Jun 2, 2026

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

Haptoglobin polymorphism as a risk factor for chronic kidney disease: a case-control study.

Yi-Chun Chen1, Ching-Chih Lee, Chih-Yuan Huang

  • 1Division of Nephrology, Department of Internal Medicine, Buddhist Dalin Tzu Chi General Hospital, Chiayi, Taiwan, ROC.

American Journal of Nephrology
|May 7, 2011
PubMed
Summary

The Hp2-2 genotype is a significant independent risk factor for chronic kidney disease (CKD) in Taiwan. Identifying haptoglobin (Hp) genotype may help predict genetic predisposition to CKD.

More Related Videos

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

Related Experiment Videos

Last Updated: Jun 2, 2026

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

Area of Science:

  • Nephrology
  • Genetics
  • Epidemiology

Background:

  • Taiwan faces the world's highest rates of end-stage renal disease.
  • Haptoglobin (Hp) plays a protective role in the kidneys, with varying functions across different Hp alleles.
  • Understanding Hp genotype associations is crucial for renal disease research.

Purpose of the Study:

  • To investigate the association between haptoglobin (Hp) genotype and chronic kidney disease (CKD) in the Taiwanese population.
  • To determine if specific Hp genotypes are risk factors for developing CKD.

Main Methods:

  • A hospital-based, age-matched case-control study involving 213 CKD patients and 213 controls.
  • Haptoglobin (Hp) genotypes were identified using polymerase chain reaction and electrophoresis.
  • Unconditional logistic regression analysis was employed to identify CKD risk factors.

Main Results:

  • The Hp2-2 genotype and Hp(2) allele were found at significantly higher frequencies in the CKD group compared to controls (p=0.032 and p=0.024, respectively).
  • After adjusting for other factors, the Hp2-2 genotype remained a significant independent risk factor for CKD (OR 3.841).
  • Diabetes (OR 3.131), hypertension (OR 1.748), and dyslipidemia (OR 1.646) were also significantly associated with CKD.

Conclusions:

  • The Hp2-2 genotype is confirmed as an independent risk factor for chronic kidney disease (CKD).
  • Hp genotype determination shows potential utility in predicting an individual's genetic risk for CKD.